Design Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	0	0	0	0.23	0.83
Revenue Growth (YoY)	-	-	-	-72.90%	-
Gross Profit	0	0	0	0.23	0.83
Selling, General & Admin	21.13	18.98	11.05	2.5	1.09
Research & Development	57.06	48.61	24.78	6.06	1.65
Operating Expenses	78.19	67.59	35.83	8.56	2.74
Operating Income	-78.19	-67.59	-35.83	-8.33	-1.91
Other Expense / Income	-11.33	-4.29	-0.3	-0.05	0.14
Pretax Income	-66.86	-63.31	-35.53	-8.28	-2.05
Net Income	-66.86	-63.31	-35.53	-8.28	-2.05
Shares Outstanding (Basic)	56	56	46	16	15
Shares Outstanding (Diluted)	56	56	46	16	15
Shares Change	0.50%	21.27%	190.80%	2.08%	-
EPS (Basic)	-1.19	-1.14	-0.77	-0.52	-0.13
EPS (Diluted)	-1.19	-1.14	-0.77	-0.52	-0.13
Free Cash Flow	-58.82	-52.2	-30.92	-8.75	-0.14
Free Cash Flow Per Share	-1.05	-0.94	-0.67	-0.55	-0.01
Gross Margin	-	-	-	100.00%	100.00%
Operating Margin	-	-	-	-3685.84%	-228.78%
Profit Margin	-	-	-	-3663.72%	-245.44%
Free Cash Flow Margin	-	-	-	-3869.47%	-16.67%
EBITDA	-66.29	-62.84	-35.39	-8.28	-2.05
EBITDA Margin	-	-	-	-3661.50%	-245.44%
Depreciation & Amortization	0.57	0.47	0.15	0.01	0
EBIT	-66.86	-63.31	-35.53	-8.28	-2.05
EBIT Margin	-	-	-	-3663.72%	-245.44%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).